Kevzara

Sarilumab, the active ingredient in Kevzara, is a IL-6 receptor antagonist presented as a injection for subcutaneous use. It is indicated for the treatment of rheumatoid arthritis in adult patients who have an inadequate response to conventional disease‑modifying antirheumatic drugs.

GNH USA supplies Kevzara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kevzara (sarilumab) targets the interleukin‑6 pathway, a key driver of inflammatory disease activity in rheumatoid arthritis.

- Rheumatoid arthritis: reduces disease activity and slows joint damage progression in adults with moderate to severe disease.

Adverse reactions may occur with sarilumab therapy. Patients should be monitored for both common and serious events.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Neutropenia: reduced neutrophil count, potentially increasing infection risk. - Elevated liver enzymes: mild to moderate increases in ALT or AST. - Upper respiratory tract infections: nasopharyngitis, sinusitis. - Headache: mild to moderate intensity. - Diarrhea: occasional loose stools.

Serious or Rare Side Effects: - Serious infections: bacterial, fungal, or viral infections requiring hospitalization. - Gastrointestinal perforation: rare but potentially life‑threatening. - Severe neutropenia: may lead to opportunistic infections. - Hepatic failure: marked elevation of liver enzymes with jaundice. - Anaphylaxis or severe hypersensitivity reactions. - Cytopenias: thrombocytopenia or anemia.

Before initiating sarilumab, clinicians should assess patient history and monitor laboratory parameters.

- Infection screening: test for latent tuberculosis and hepatitis before starting therapy. - Blood count monitoring: regular CBC to detect neutropenia or cytopenias. - Liver function: periodic ALT/AST assessments to identify hepatotoxicity. - Vaccination: avoid live vaccines during treatment; administer inactivated vaccines as needed. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sarilumab may interact with other agents that affect immune function or infection risk.

Major Interactions (Avoid): - Live vaccines: concurrent use can cause severe infection. - Other biologic immunomodulators: combined immunosuppression may increase infection risk. - Strong immunosuppressants (e.g., high‑dose corticosteroids): may exacerbate neutropenia.

Moderate Interactions (Monitor Closely): - CYP450 substrates: sarilumab may modestly affect metabolism of certain drugs. - Anticoagulants: monitor for bleeding if liver enzymes are elevated. - Concomitant antibiotics: adjust dosing if neutropenia develops.